Recently Added Drugs
1. Arakoda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12616689 | 60 DEGREES PHARMA | NA |
Dec, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 08, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
Drugs and Companies using TAFENOQUINE SUCCINATE ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 08 August, 2018
Treatment: For the oral prevention/prophylaxis of malaria in adults, comprising a three-phase dosing regimen consisting of a loading/initial dose, a maintenance/exposure dose, and a terminal/post-exposure dose
Dosage: TABLET
More Information on Dosage
ARAKODA family patents
2. Arikayce Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12616708 | INSMED | NA |
May, 2035
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination drug regimen
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
3. Atorvaliq patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12599553 | CMP DEV | Aqueous Suspension Suitable For Oral Administration |
Jun, 2037
(10 years from now) | |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
ATORVALIQ family patents
4. Auvelity patent expiration
AUVELITY's oppositions filed in EPO
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8569328 | AXSOME | Compositions and methods comprising tilidine or related compounds and dextromethorphan |
Jul, 2032
(6 years from now) | |
| US11007189 | AXSOME | Bupropion As A Modulator Of Drug Activity |
Nov, 2034
(8 years from now) | |
| US10058518 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US10080727 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US10092560 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US10105361 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US10251879 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US10780066 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US11207281 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11234946 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11253492 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11273133 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11273134 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11285118 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11285146 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11291638 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11291665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11298352 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11344544 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11382874 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11419867 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11426370 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US11571417 | AXSOME | Bupropion As A Modulator Of Drug Activity |
Nov, 2034
(8 years from now) | |
| US11590124 | AXSOME | Bupropion As A Modulator Of Drug Activity |
Nov, 2034
(8 years from now) | |
| US11617747 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US9168234 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US9198905 | AXSOME | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9205083 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(8 years from now) | |
| US9238032 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(8 years from now) | |
| US9314462 | AXSOME | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9370513 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9375429 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(8 years from now) | |
| US9408815 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(8 years from now) | |
| US9421176 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9457023 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9457025 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(8 years from now) | |
| US9474731 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9486450 | AXSOME | Hydroxybupropion and related compounds as modulators of drug plasma levels |
Nov, 2034
(8 years from now) | |
| US9700528 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9700553 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9707191 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9763932 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9861595 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9867819 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US9968568 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(8 years from now) | |
| US12433884 | AXSOME | Compounds And Combinations Thereof For Treating Neurological And Psychiatric Conditions |
Jun, 2040
(13 years from now) | |
| US12472156 | AXSOME | Compounds And Combinations Thereof For Treating Neurological And Psychiatric Conditions |
Jun, 2040
(13 years from now) | |
| US12576078 | AXSOME | NA |
Jun, 2040
(13 years from now) | |
| US12239642 | AXSOME | Bupropion Dosage Forms With Reduced Food And Alcohol Dosing Effects |
Jan, 2043
(16 years from now) | |
| US12263161 | AXSOME | Bupropion Dosage Forms With Reduced Food And Alcohol Dosing Effects |
Jan, 2043
(16 years from now) | |
| US12472174 | AXSOME | Bupropion Dosage Forms With Reduced Food And Alcohol Dosing Effects |
Jan, 2043
(16 years from now) | |
| US12478622 | AXSOME | Bupropion Dosage Forms With Reduced Food And Alcohol Dosing Effects |
Jan, 2043
(16 years from now) | |
| US12564587 | AXSOME | Bupropion Dosage Forms With Reduced Food And Alcohol Dosing Effects |
Jan, 2043
(16 years from now) | |
| US12194005 | AXSOME | Compounds And Combinations Thereof For Treating Neurological And Psychiatric Conditions |
Jan, 2043
(16 years from now) | |
| US12364674 | AXSOME | Compounds And Combinations Thereof For Treating Neurological And Psychiatric Conditions |
Jan, 2043
(16 years from now) | |
| US12370154 | AXSOME | Treatment Of Poor Metabolizers Of Dextromethorphan With A Combination Of Bupropion And Dextromethorphan |
Feb, 2043
(16 years from now) | |
| US12599576 | AXSOME | Treatment Of Poor Metabolizers Of Dextromethorphan With A Combination Of Bupropion And Dextromethorphan |
Feb, 2043
(16 years from now) | |
| US12472155 | AXSOME | Compounds And Combinations Thereof For Treating Neurological And Psychiatric Conditions |
Feb, 2043
(16 years from now) | |
| US12194036 | AXSOME | Combination Of Dextromethorphan And Bupropion For Treating Depression |
Apr, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
| New Indication(I-913) | Apr 30, 2029 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 30 April, 2026
Treatment: The treatment of agitation associated with dementia due to alzheimer’s disease; The treatment of agitation associated with dementia due to alzheimer’s disease by reducing a trough effect of dextrometh...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before its drug patent expiration?
More Information on Dosage
AUVELITY family patents
5. Baxfendy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9353081 | ASTRAZENECA | Bicyclic Dihydroquinoline-2-One Derivatives |
Feb, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2031 |
Drugs and Companies using BAXDROSTAT ingredient
NCE-1 date: 15 May, 2030
Market Authorisation Date: 15 May, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
BAXFENDY family patents
6. Beqalzi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11420968 | BEONE MEDICINES | Bcl-2 Inhibitors |
Apr, 2039
(12 years from now) | |
Drugs and Companies using SONROTOCLAX ingredient
Market Authorisation Date: 13 May, 2026
Treatment: NA
Dosage: TABLET
More Information on Dosage
BEQALZI family patents
7. Brekiya (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541043 | AMNEAL | Low Concentration Delivery Of An Ergoline Derivative For Treatment Of A Headache |
Mar, 2039
(12 years from now) | |
| US12329749 | AMNEAL | Low Concentration Delivery Of An Ergoline Derivative For Treatment Of A Headache |
May, 2039
(12 years from now) | |
| US11083712 | AMNEAL | NA |
Jun, 2039
(13 years from now) | |
| US12414941 | AMNEAL | Low Concentration Delivery Of An Ergoline Derivative For Treatment Of A Headache |
Aug, 2039
(13 years from now) | |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 14 May, 2025
Treatment: Acute treatment of cluster headaches in adults
Dosage: SOLUTION
More Information on Dosage
BREKIYA (AUTOINJECTOR) family patents
8. Breztri Aerosphere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(3 years from now) | |
| US8324266 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(3 years from now) | |
| US8703806 | ASTRAZENECA | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(3 years from now) | |
| US8808713 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(3 years from now) | |
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(3 years from now) | |
| US9463161 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(3 years from now) | |
| US8815258 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(4 years from now) | |
| US11331442 | ASTRAZENECA | Drug delivery systems and related methods |
Oct, 2038
(12 years from now) | |
| US11833292 | ASTRAZENECA | Drug delivery systems and related methods |
Oct, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jul 23, 2023 |
| New Strength(NS) | Apr 27, 2029 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Market Authorisation Date: 27 April, 2026
Treatment: Use for the maintenance treatment of asthma in patients 12 years of age or older
Dosage: AEROSOL, METERED
More Information on Dosage
BREZTRI AEROSPHERE family patents
9. Bysanti patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12606869 | VANDA | Methods For The Administration Of Iloperidone |
Sep, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 20, 2031 |
Drugs and Companies using MILSAPERIDONE ingredient
NCE-1 date: 20 February, 2030
Market Authorisation Date: 20 February, 2026
Treatment: Method of treating acute episodes of manic or mixed episodes associated with bipolar i disorder in adults by administering milsaperidone to a patient by reducing the dose in patients who are poor meta...
Dosage: TABLET
More Information on Dosage
BYSANTI family patents
10. Cabenuva Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12636285 | VIIV | NA |
Oct, 2040
(14 years from now) | |
| US12636286 | VIIV | NA |
Oct, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-184) | Jan 31, 2025 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
CABENUVA KIT family patents
11. Cabtreo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12616710 | BAUSCH | NA |
Jul, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2026 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 20 October, 2023
Treatment: NA
Dosage: GEL
How can I launch a generic of CABTREO before its drug patent expiration?
More Information on Dosage
CABTREO family patents
12. Camcevi Etm patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10646572 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(6 months from now) | |
| US9744207 | ACCORD | Pharmaceutical compositions with enhanced stability |
Jan, 2027
(6 months from now) | |
| US9572857 | ACCORD | Pharmaceutical compositions with enhanced stability |
Aug, 2029
(3 years from now) | |
| US12133878 | ACCORD | Pharmaceutical compositions having a selected release duration |
Dec, 2037
(11 years from now) | |
| US11717555 | ACCORD | Pharmaceutical compositions having a selected release duration |
Jan, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 25, 2028 |
Drugs and Companies using LEUPROLIDE MESYLATE ingredient
Market Authorisation Date: 25 August, 2025
Treatment: NA
Dosage: EMULSION
More Information on Dosage
CAMCEVI ETM family patents
13. Danziten patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629369 | AZURITY | Pharmaceutical Compositions Of Nilotinib |
Feb, 2040
(13 years from now) | |
Drugs and Companies using NILOTINIB TARTRATE ingredient
Market Authorisation Date: 07 November, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
DANZITEN family patents
14. Daptomycin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629337 | HIKMA | Daptomycin Formulation |
Jan, 2043
(16 years from now) | |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 30 January, 2023
Treatment: NA
Dosage: POWDER
More Information on Dosage
DAPTOMYCIN family patents
15. Descovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629338 | GILEAD | NA |
Jun, 2036
(10 years from now) | |
| US12648911 | GILEAD | NA |
Jun, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 28, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Indication(I-812) | Oct 03, 2022 |
| Orphan Drug Exclusivity(ODE-284) | Sep 28, 2024 |
| Orphan Drug Exclusivity(ODE-285) | Sep 28, 2024 |
| M(M-316) | Jun 20, 2028 |
| Orphan Drug Exclusivity(ODE-457) | Jan 07, 2029 |
Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient
NCE-1 date: 06 November, 2019
Market Authorisation Date: 07 January, 2022
Treatment: Prophylaxis of hiv-1 infection
Dosage: TABLET
How can I launch a generic of DESCOVY before its drug patent expiration?
More Information on Dosage
DESCOVY family patents
16. Duvyzat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12606519 | ITALFARMACO | Process For Preparing {6-[(Diethylamino) Methyl]Naphthalen-2-Yl}Methyl [4-(Hydroxycarbamoyl)Phenyl] Carbamate Having High Purity |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2029 |
| Orphan Drug Exclusivity(ODE-473) | Mar 21, 2031 |
Drugs and Companies using GIVINOSTAT HYDROCHLORIDE ingredient
NCE-1 date: 21 March, 2028
Market Authorisation Date: 21 March, 2024
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
DUVYZAT family patents
17. Evdi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303506 | APOTEX | Trabectedin Composition |
Feb, 2043
(16 years from now) | |
Drugs and Companies using TRABECTEDIN ingredient
Market Authorisation Date: 01 May, 2026
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVDI family patents
18. Fanapt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12606869 | VANDA | Methods For The Administration Of Iloperidone |
Sep, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
| M(M-180) | May 26, 2019 |
| New Indication(I-939) | Apr 02, 2027 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating acute episodes of manic or mixed episodes associated with bipolar i disorder in adults by administering iloperidone to a patient by reducing the dose in patients who are poor metabo...
Dosage: TABLET
How can I launch a generic of FANAPT before its drug patent expiration?
More Information on Dosage
FANAPT family patents
19. Filspari patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9662312 | TRAVERE | Method For Treating Glomerulosclerosis |
Mar, 2030
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 17, 2028 |
| Orphan Drug Exclusivity(ODE-389) | Feb 17, 2030 |
| Orphan Drug Exclusivity(ODE-493) | Sep 05, 2031 |
Drugs and Companies using SPARSENTAN ingredient
NCE-1 date: 17 February, 2027
Market Authorisation Date: 17 February, 2023
Treatment: To reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (fsgs) without nephrotic syndrome
Dosage: TABLET
More Information on Dosage
FILSPARI family patents
20. Idvynso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7339053 | MERCK | 4'-C-Substituted-2-Haloadenosine Derivative |
May, 2027
(11 months from now) | |
| US8486975 | MERCK | Non-nucleoside reverse transcriptase inhibitors |
Aug, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 20, 2031 |
Drugs and Companies using DORAVIRINE; ISLATRAVIR ingredient
NCE-1 date: 20 April, 2030
Market Authorisation Date: 20 April, 2026
Treatment: Use of a complete two-drug regimen for the treatment of hiv-1 infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral reg...
Dosage: TABLET
More Information on Dosage
IDVYNSO family patents
21. Jakafi Xr patent expiration
JAKAFI XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598257 | INCYTE | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Dec, 2027
(1 year, 5 months from now) | |
| US8415362 | INCYTE | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
Dec, 2027
(1 year, 5 months from now) | |
| US8722693 | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11744832 | INCYTE | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(5 months from now) | |
| US8530485 | INCYTE | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors |
Dec, 2026
(5 months from now) | |
| US9079912 | INCYTE | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
Dec, 2026
(5 months from now) | |
| US9206187 | INCYTE | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase |
Dec, 2026
(5 months from now) | |
| US9814722 | INCYTE | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
Dec, 2026
(5 months from now) | |
| US10016429 | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | |
| US11213528 | INCYTE | Salts Of The Janus Kinase Inhibitor (R)-3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-3-Cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | |
| US8822481 | INCYTE | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | |
| US8829013 | INCYTE | Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
Jun, 2028
(1 year, 11 months from now) | |
| US10874616 | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | |
| US11576864 | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | |
| US11576865 | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | |
| US11896717 | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
Nov, 2033
(7 years from now) | |
| US11337927 | INCYTE | Sustained-Release Dosage Forms Of Ruxolitinib |
Jan, 2034
(7 years from now) | |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 01 May, 2026
Treatment: For treatment of steroid-refractory acute graft-versus-host disease (agvhd); For treatment of chronic graft-versus-host disease (cgvhd) after failure of one or two lines of systemic therapy; For treat...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
JAKAFI XR family patents
22. Jylamvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12605385 | SHORLA | Methotrexate Formulation |
Oct, 2035
(9 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 29 November, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
JYLAMVO family patents
23. Kisqali patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8324225 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Dec, 2028
(2 years from now) | |
|
US9416136 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Feb, 2030
(3 years from now) | |
|
US8962630 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Jun, 2030
(3 years from now) | |
|
US8685980 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Nov, 2030
(4 years from now) | |
|
US8415355 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Sep, 2031
(5 years from now) | |
|
US9193732 (Pediatric) | NOVARTIS | Salt(S) Of 7-Cyclopentyl-2-(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
May, 2032
(5 years from now) | |
|
US9868739 (Pediatric) | NOVARTIS | Salt(S) Of 7-Cyclopentyl-2-(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
May, 2032
(5 years from now) | |
|
US12544379 (Pediatric) | NOVARTIS | Combination Therapy Using Ribociclib And Fulvestrant For The Treatment Of Hr+ Breast Cancer |
Feb, 2035
(8 years from now) | |
|
US12544380 (Pediatric) | NOVARTIS | Combination Therapy Using Ribociclib And An Aromatase Inhibitor For The Treatment Of Hr+ Breast Cancer |
Feb, 2035
(8 years from now) | |
|
US10799506 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
|
US12064434 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
|
US12419894 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-783) | Jul 18, 2021 |
| New Indication(I-784) | Jul 18, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-950) | Sep 17, 2027 |
| Pediatric Exclusivity(PED) | Mar 17, 2028 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of KISQALI before its drug patent expiration?
More Information on Dosage
KISQALI family patents
24. Kisqali Femara Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8324225 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Dec, 2028
(2 years from now) | |
|
US9416136 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Feb, 2030
(3 years from now) | |
|
US8962630 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Jun, 2030
(3 years from now) | |
|
US8685980 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Nov, 2030
(4 years from now) | |
|
US8415355 (Pediatric) | NOVARTIS | Pyrrolopyrimidine Compounds And Their Uses |
Sep, 2031
(5 years from now) | |
|
US9193732 (Pediatric) | NOVARTIS | Salt(S) Of 7-Cyclopentyl-2-(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
May, 2032
(5 years from now) | |
|
US9868739 (Pediatric) | NOVARTIS | Salt(S) Of 7-Cyclopentyl-2-(5-Piperazin-1-Yl-Pyridin-2-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidine-6-Carboxylic Acid Dimethylamide And Processes Of Making Thereof |
May, 2032
(5 years from now) | |
|
US12544380 (Pediatric) | NOVARTIS | Combination Therapy Using Ribociclib And An Aromatase Inhibitor For The Treatment Of Hr+ Breast Cancer |
Feb, 2035
(8 years from now) | |
|
US10799506 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
|
US12064434 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
|
US12419894 (Pediatric) | NOVARTIS | Ribociclib Tablet |
Oct, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2022 |
| New Patient Population(NPP) | Dec 10, 2024 |
| New Indication(I-951) | Sep 17, 2027 |
| Pediatric Exclusivity(PED) | Mar 17, 2028 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: 13 March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before its drug patent expiration?
More Information on Dosage
KISQALI FEMARA CO-PACK (COPACKAGED) family patents
25. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12599606 | JANSSEN | Therapies With 3Rd Generation Egfr Tyrosine Kinase Inhibitors |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: First-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 l858r substitution mutations, by administration of eq 240 m...
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
26. Macrilen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8192719 (Pediatric) | AETERNA ZENTARIS | Methods And Kits To Diagnose Growth Hormone Deficiency By Oral Administration Of Ep 1572 Or Ep 1573 Compounds |
Apr, 2028
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2022 |
| Orphan Drug Exclusivity(ODE-170) | Dec 20, 2024 |
Drugs and Companies using MACIMORELIN ACETATE ingredient
NCE-1 date: 20 December, 2021
Market Authorisation Date: 20 December, 2017
Treatment: NA
Dosage: FOR SOLUTION
More Information on Dosage
MACRILEN family patents
27. Miplyffa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11707456 | ZEVRA | Processes For Preparing Arimoclomol Citrate And Intermediates Thereof |
Nov, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 20, 2029 |
| Orphan Drug Exclusivity(ODE-496) | Sep 20, 2031 |
Drugs and Companies using ARIMOCLOMOL CITRATE ingredient
NCE-1 date: 20 September, 2028
Market Authorisation Date: 20 September, 2024
Treatment: Use of arimoclomol, in combination with miglustat, for treatment of neurological manifestations of niemann-pick disease type c (npc)
Dosage: CAPSULE
More Information on Dosage
MIPLYFFA family patents
28. Mounjaro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629404 | ELI LILLY | Gip/Glp1 Agonist Compositions |
Jun, 2039
(12 years from now) | |
| US12616740 | ELI LILLY | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| New Patient Population(NPP) | Dec 19, 2028 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: A method for treating type-2 diabetes by administering an effective dose of tirzepatide, about 6.2 - 9.5 mg/ml nacl, and dibasic sodium phosphate wherein the composition is free from preservative; Imp...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO family patents
29. Mounjaro (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629404 | ELI LILLY | Gip/Glp1 Agonist Compositions |
Jun, 2039
(12 years from now) | |
| US12616740 | ELI LILLY | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| New Patient Population(NPP) | Dec 19, 2028 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: A method for treating type-2 diabetes by administering an effective dose of tirzepatide, about 6.2 - 9.5 mg/ml nacl, and dibasic sodium phosphate wherein the composition is free from preservative; Imp...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO (AUTOINJECTOR) family patents
30. Mounjaro Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12616740 | ELI LILLY | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| New Patient Population(NPP) | Dec 19, 2028 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Improving glycemic control in a type 2 diabetes patient by subcutaneously administering tirzepatide at 2.5 mg once weekly for at least four weeks and increasing the dose in 2.5 increments for 4 weeks ...
Dosage: SOLUTION
More Information on Dosage
MOUNJARO KWIKPEN family patents
31. Nexterone patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117951 | BAXTER | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(2 years from now) | |
Drugs and Companies using AMIODARONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 December, 2008
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of NEXTERONE before its drug patent expiration?
More Information on Dosage
NEXTERONE family patents
32. Nubeqa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12611397 | BAYER | NA |
Jul, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
| New Indication(I-971) | Jun 03, 2028 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of NUBEQA before its drug patent expiration?
More Information on Dosage
NUBEQA family patents
33. Omeprazole patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12599565 | DEXCEL | Stable Benzimidazole Formulation |
Jan, 2030
(3 years from now) | |
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 04 December, 2007
Treatment: NA
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
OMEPRAZOLE family patents
34. Orgovyx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629370 | SUMITOMO AM | Treatment Of Prostate Cancer |
Sep, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer
Dosage: TABLET
How can I launch a generic of ORGOVYX before its drug patent expiration?
More Information on Dosage
ORGOVYX family patents
35. Orladeyo patent expiration
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(8 years from now) | |
| US12116346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(8 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(8 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(8 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(8 years from now) | |
| US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(8 years from now) | |
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US12344585 | BIOCRYST | Crystalline Salts Of A Plasma Kallikrein Inhibitor |
Nov, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 11, 2029 |
| New Product(NP) | Dec 11, 2028 |
Drugs and Companies using BEROTRALSTAT DIHYDROCHLORIDE ingredient
Market Authorisation Date: 11 December, 2025
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 2 years of age and older
Dosage: PELLETS
How can I launch a generic of ORLADEYO before its drug patent expiration?
More Information on Dosage
ORLADEYO family patents
36. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033499 | NOVO NORDISK | Tablet Formulation Comprising A Glp-1 Peptide And A Delivery Agent |
Jun, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
| New Indication(I-976) | Oct 17, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of OZEMPIC before its drug patent expiration?
More Information on Dosage
OZEMPIC family patents
37. Qulipta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12622897 | ABBVIE | Methods Of Treating Migraine |
Sep, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Treatment: Preventive treatment of migraine in adults undergoing concurrent treatment with an oatp inhibitor
Dosage: TABLET
How can I launch a generic of QULIPTA before its drug patent expiration?
More Information on Dosage
QULIPTA family patents
38. Rezenopy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12622903 | SCIENTURE | Drug Products For Intranasal Administration And Uses Thereof |
Feb, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 19, 2027 |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 April, 2024
Treatment: NA
Dosage: SPRAY
More Information on Dosage
REZENOPY family patents
39. Romvimza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12617775 | DECIPHERA | NA |
Dec, 2044
(18 years from now) | |
| US12643883 | DECIPHERA | NA |
Dec, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2030 |
Drugs and Companies using VIMSELTINIB ingredient
NCE-1 date: 14 February, 2029
Market Authorisation Date: 14 February, 2025
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
ROMVIMZA family patents
40. Rybelsus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033499 | NOVO NORDISK | Tablet Formulation Comprising A Glp-1 Peptide And A Delivery Agent |
Jun, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
| New Indication(I-976) | Oct 17, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
How can I launch a generic of RYBELSUS before its drug patent expiration?
More Information on Dosage
RYBELSUS family patents
41. Sezaby patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12636254 | SUN PHARMA | NA |
Apr, 2042
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-414) | Nov 17, 2029 |
Drugs and Companies using PHENOBARBITAL SODIUM ingredient
Market Authorisation Date: 17 November, 2022
Treatment: Method of treating neonatal seizures
Dosage: POWDER
More Information on Dosage
SEZABY family patents
42. Sublocade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12622904 | INDIVIOR | Buprenorphine Dosing Regimens |
Nov, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2020 |
| M(M-314) | Feb 21, 2028 |
Drugs and Companies using BUPRENORPHINE ingredient
Market Authorisation Date: 30 November, 2017
Treatment: Treatment of moderate to severe opioid use disorder by once-monthly subcutaneous administration of buprenorphine free base
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
SUBLOCADE family patents
43. Symbicort Aerosphere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716753 | ASTRAZENECA | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(3 years from now) | |
| US9415009 | ASTRAZENECA | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-988) | Apr 27, 2029 |
| New Strength(NS) | Apr 27, 2029 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE ingredient
Market Authorisation Date: 27 April, 2026
Treatment: Treatment of asthma in adult and pediatric patients aged 12 years and older
Dosage: AEROSOL, METERED
More Information on Dosage
SYMBICORT AEROSPHERE family patents
44. Symbravo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10265399 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US10265400 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US10307484 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US10369225 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US10456471 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US11266657 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US11433078 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US11433079 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US11944683 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US12616752 | AXSOME | NA |
May, 2038
(11 years from now) | |
| US12611413 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Dec, 2041
(15 years from now) | |
| US12005118 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Jan, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2028 |
Drugs and Companies using MELOXICAM; RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 30 January, 2025
Treatment: Improving oral bioavailability of meloxicam for the acute treatment of migraine; Improving the pharmacokinetics of meloxicam in a human being suffering from migraine; Acute treatment of migraine; Rapi...
Dosage: TABLET
How can I launch a generic of SYMBRAVO before its drug patent expiration?
More Information on Dosage
SYMBRAVO family patents
45. Tepylute patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12622921 | SHORLA | Stable Formulations Comprising Thiotepa |
Aug, 2041
(15 years from now) | |
Drugs and Companies using THIOTEPA ingredient
Market Authorisation Date: 25 June, 2024
Treatment: Treatment of adenocarcinoma of the breast or ovary
Dosage: SOLUTION
More Information on Dosage
TEPYLUTE family patents
46. Upneeq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12605363 | RVL | Oxymetazoline Compositions |
Dec, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 08, 2023 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 July, 2020
Treatment: NA
Dosage: SOLUTION/DROPS
More Information on Dosage
UPNEEQ family patents
47. Veppanu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11597720 | ARVINAS OPERATIONS | Tetrahydronaphthalene And Tetrahydroisoquinoline Derivatives As Estrogen Receptor Degraders |
Dec, 2037
(11 years from now) | |
| US10647698 | ARVINAS OPERATIONS | Tetrahydronaphthalene And Tetrahydroisoquinoline Derivatives As Estrogen Receptor Degraders |
Jan, 2038
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10899742 | ARVINAS OPERATIONS | NA |
Dec, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 01, 2031 |
Drugs and Companies using VEPDEGESTRANT ingredient
NCE-1 date: 01 May, 2030
Market Authorisation Date: 01 May, 2026
Treatment: Treatment of adults with er-positive, her2-negative esr1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Dosage: TABLET
More Information on Dosage
VEPPANU family patents
48. Wegovy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033499 | NOVO NORDISK | Tablet Formulation Comprising A Glp-1 Peptide And A Delivery Agent |
Jun, 2033
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Product(NP) | Dec 22, 2028 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Indication(I-973) | Aug 15, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
Market Authorisation Date: 22 December, 2025
Treatment: Method of weight reduction and maintenance of weight reduction
Dosage: TABLET
How can I launch a generic of WEGOVY before its drug patent expiration?
More Information on Dosage
WEGOVY family patents
49. Xhance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12616806 | PARATEK | NA |
Feb, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway to treat chronic rhinosinusitis without nasal polyps in adults
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
50. Xyosted (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629483 | ANTARES | Syringe Shock Absorber For Use In An Injection Device |
Aug, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XYOSTED (AUTOINJECTOR) family patents
51. Zepbound patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629404 | ELI LILLY | Gip/Glp1 Agonist Compositions |
Jun, 2039
(12 years from now) | |
| US12616740 | ELI LILLY | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: A method for treating obesity by administering an effective dose of tirzepatide and about 6.2 - 9.5 mg/ml nacl, wherein the composition has a ph of about 6.5 - 7.5 and is free from preservative; Treat...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND family patents
52. Zepbound (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12629404 | ELI LILLY | Gip/Glp1 Agonist Compositions |
Jun, 2039
(12 years from now) | |
| US12616740 | ELI LILLY | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: A method for treating obesity by administering an effective dose of tirzepatide and about 6.2 - 9.5 mg/ml nacl, wherein the composition has a ph of about 6.5 - 7.5 and is free from preservative; Treat...
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND (AUTOINJECTOR) family patents
53. Zepbound Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12616740 | ELI LILLY | NA |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
| M(M-82) | Oct 18, 2027 |
| New Indication(I-958) | Dec 20, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: Treatment of obesity by subcutaneously administering tirzepatide at 2.5 mg once weekly for at least four weeks and increasing the dose in 2.5 increments for 4 weeks each to 5 mg, 7.5 mg, 10 mg, or 12....
Dosage: SOLUTION
More Information on Dosage
ZEPBOUND KWIKPEN family patents
54. Zerbaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7129232 (Pediatric) | CUBIST | Cephem Compounds |
Nov, 2028
(2 years from now) | |
|
US10028963 (Pediatric) | CUBIST | Methods For Treating Intrapulmonary Infections |
Mar, 2033
(6 years from now) | |
|
US9724353 (Pediatric) | CUBIST | Methods For Treating Intrapulmonary Infections |
Mar, 2033
(6 years from now) | |
|
US10420841 (Pediatric) | CUBIST | Ceftolozane Antibiotic Compositions |
Sep, 2034
(8 years from now) | |
|
US11278622 (Pediatric) | CUBIST | Ceftolozane Antibiotic Compositions |
Sep, 2034
(8 years from now) | |
|
US8968753 (Pediatric) | CUBIST | Ceftolozane-Tazobactam Pharmaceutical Compositions |
Sep, 2034
(8 years from now) | |
|
US9320740 (Pediatric) | CUBIST | Ceftolozane-Tazobactam Pharmaceutical Compositions |
Sep, 2034
(8 years from now) | |
|
US9872906 (Pediatric) | CUBIST | Ceftolozane Antibiotic Compositions |
Sep, 2034
(8 years from now) | |
|
US8906898 (Pediatric) | CUBIST | NA |
Nov, 2034
(8 years from now) | |
|
US10376496 (Pediatric) | CUBIST | Treating Infections With Ceftolozane/Tazobactam In Subjects Having Impaired Renal Function |
Mar, 2035
(8 years from now) | |
|
US10933053 (Pediatric) | CUBIST | Treating Infections With Ceftolozane/Tazobactam In Subjects Having Impaired Renal Function |
Mar, 2035
(8 years from now) | |
|
US10125149 (Pediatric) | CUBIST | Synthesis Of Cephalosporin Compounds |
Feb, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
| New Patient Population(NPP) | Apr 21, 2025 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: POWDER
More Information on Dosage
ZERBAXA family patents